CPT code 0141U identifies a proprietary molecular diagnostic assay — the ePlex® BCID gram–positive panel from GenMark Diagnostics — used for rapid detection of multiple gram-positive bacterial targets, select resistance genes, and pan-targets for gram-negative bacteria and Candida from positive blood cultures. As a PLA code, 0141U applies only to this specific commercial test and matters nationally because rapid, targeted pathogen identification can influence antimicrobial management and hospital infection care pathways. Coverage and payment for PLA tests are closely watched by national payers and Medicare due to clinical impact and cost considerations. Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical role of the assay, how CPT code 0141U is used in billing, typical sites of service where the test is performed, and what to expect from national payer engagement. The publication also outlines benchmarking topics and policy considerations relevant to proprietary laboratory analyses, including coding specificity, payer coverage patterns, and implications for laboratory workflow and hospital diagnostic protocols. Data not available in the input for specific payer policies, reimbursement rates, associated taxonomies, and ICD-10 pairings are noted where applicable.